Crossmark

Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)

Crossref DOI link: https://doi.org/10.1186/s13053-019-0104-x

Published Online: 2019-01-18

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ramírez-Calvo, Marta https://orcid.org/0000-0002-7179-5360
García-Casado, Zaida

Fernández-Serra, Antonio

de Juan, Inmaculada

Palanca, Sarai

Oltra, Silvestre

Soto, José Luis

Castillejo, Adela

Barbera, Víctor M

Juan-Fita, Ma José

Segura, Ángel

Chirivella, Isabel

Sánchez, Ana Beatriz

Tena, Isabel

Chaparro, Carolina

Salas, Dolores

López-Guerrero, José Antonio
License Information

Text and Data Mining valid from 2019-01-18
More Information

Article History

Received: 13 August 2018

Accepted: 9 January 2019

First Online: 18 January 2019

Ethics approval and consent to participate

: This study (Fam-Can) was approved by the Ethical Committee of the Public Health General Management on March 30th, 2015 and all probands gave informed consent for using their DNA for research purposes.

: Not applicable.

: No potential conflict of interest has been identified for any author of this paper according to the conventions and standards of the Hereditary Cancer in Clinical Practice.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below